GlassScriptPhysician profile
Douglas Michael Trate
NPI 1477531242
$2,659.09
in general payments reported to CMS, 2019-2025
21 companies · $736 in 2025
The $736 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $39.04 · 2021: $11.44 · 2022: $292 · 2023: $496 · 2024: $540 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,771.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $736.80 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Pfizer INC. | $314.65 | 2019-2025 | |
| Janssen Biotech, INC. | $257.04 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $209.38 | 2024-2025 | Omvoh |
| Celgene Corporation | $180.88 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $165.08 | 2019-2025 | Eohilia, Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.31 | 2019-2024 | Trulance |
| Ardelyx, INC. | $116.03 | 2023 | Ibsrela |
| Genzyme Corporation | $94.08 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $92.84 | 2022 | |
| Amgen INC. | $71.74 | 2025 | Uplizna |
| Aimmune Therapeutics, INC. | $52.96 | 2024 | |
| Ironwood Pharmaceuticals, INC | $40.67 | 2023-2024 | Linzess |
| Braintree Laboratories, INC. | $38.77 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $30.64 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $29.16 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.28 | 2025 | Dupixent |
| Novo Nordisk INC | $24.47 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $17.53 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.51 | 2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Trate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.